MOG

MOG

MOG Informations sur la molécule

Molecule Name
Myelin-oligodendrocyte glycoprotein
Alias de la molécule
MOG,BTN6,BTNL11,MOGIG2,NRCLP7,Myelin oligodendrocyte glycoprotein
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
NRCLP7,Myelin-oligodendrocyte glycoprotein,MOG,Myelin Oligodendrocyte Glycoprotein,MOG Ig-AluB,MOG Alpha-5,MOG AluA,MOG AluB,BTNL11,MOGIG2,BTN6
Contexte de la molécule
Myelin oligodendrocyte glycoprotein (MOG), is a single-pass transmembrane glycoprotein of the immunoglobulin (Ig) superfamily. MOG is a myelin protein exclusively expressed in the CNS at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation.

MOG Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
MOG autologous T-lymphocyte cell therapy (ImCyse)Phase 2 ClinicalImcyse Sa
Multiple Sclerosis
Details